Drugs / WT1-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00562640 | Oct 2007 → Aug 2021 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1-specific T cells | “Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0.” NCT00562640 ↗ |
| Route | Intravenous | “the first intravenous infusion of WT1-sensitized T cells” PMID 34433633 ↗ Aug 2021 |
| Target | WT1 | “autologous T cells sensitized with peptides encoding Wilms' tumor protein 1 (WT1)” PMID 34433633 ↗ Aug 2021 |